Key facts
- This page summarizes Julianne Bruno's Form 3 filing for InMed Pharmaceuticals Inc. (MTRI).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Nov 2026, 16:01.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
Footnote F2
Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 23,689 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney